Neuroprotective properties of cannabinoids in cellular and animal models : hypotheses and facts
Abstract: Progressive neuronal loss is a typical characteristic of neurodegenerative diseases. In Parkinson’s disease, the loss of dopaminergic neurons in the basal ganglia results in impaired mobility and flawed muscle control. The loss of cholinergic neurons largely in the basal forebrain contr...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Parte de libro |
| Lenguaje: | Inglés |
| Publicado: |
Matilde Otero-Losada. Universidad de Buenos Aires
2021
|
| Materias: | |
| Acceso en línea: | https://repositorio.uca.edu.ar/handle/123456789/11313 |
| Aporte de: |
| Sumario: | Abstract: Progressive neuronal loss is a typical characteristic of neurodegenerative diseases.
In Parkinson’s disease, the loss of dopaminergic neurons in the basal ganglia results
in impaired mobility and flawed muscle control. The loss of cholinergic neurons
largely in the basal forebrain contributes to memory and attention deficits and the
overall cognitive impairment in Alzheimer’s disease. This being said, neuroprotective
drugs should be expected to preserve and/or restore the functions affected by
neuronal loss, and substantially prevent cell death. The endocannabinoid system,
comprising lipid mediators able to bind to and activate cannabinoid receptors,
has emerged as a therapeutic target of potential interest in a variety of central
nervous system diseases. |
|---|